{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 113 of 169', 'ADA-positive subjects across the trial may also be divided into persistent positive versus', 'transient positive. A subject will be considered as persistent positive if he/she has positive', 'ADA for at least 2 consecutive visits with ADA assessment. Otherwise, the subject will be', 'considered as transient ADA positive. The associations between ADA and AE/SAEs may be', 'summarised for both persistent positive subjects versus transient positives subjects.', 'For subjects who develop ADA, the IGA score and change in EASI at end of treatment will be', 'listed.', 'Evaluations of nAB will be conducted on those serum samples that test positive for ADA. The', 'test sample is deemed positive or negative for the presence of nAb to tralokinumab relative to', 'a pre-determined (in assay validation), statistically derived cut point.', 'For ADA, all subjects with titre information will be listed.', '12.3.8 Interim analysis', 'No interim analysis is planned.', \"12.3.9 Analysis of data per last subject's Week 52 visit\", 'To support submission for regulatory approval, the trial will be unblinded once all randomised', 'subjects have completed the Week 52 visit. All pre-specified analyses related to the initial and', \"maintenance treatment period will be based on the data cut-off date of the last subject's\", 'Week 52 visit. The CTR will include all data from all randomised subjects from the initial and', 'maintenance treatment period and all available data from the open-label treatment period and', 'safety follow-up period as per data cut-off date.', 'Once all subjects have completed the open-label treatment period and safety follow-up period,', 'an addendum to the original CTR will be written, summarising the final results from the', 'open-label treatment period and safety follow-up period.', '12.3.10', 'General principles', 'Unless otherwise stated, all significance tests will be two-sided using the 5% significance', 'level. All CIs will be presented with 95% degree of confidence.', 'An observed-cases approach will be used for tabulations of data by visit (i.e. involving only', 'those subjects who attended each specific visit).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 114 of 169', 'Categorical data will be summarised using the number and percentage of subjects in each', 'category and treatment group. Continuous data will be summarised using the mean, median,', 'standard deviation, minimum and maximum values.', 'All the analyses specified in the protocol will be reviewed in relation to the blinded data', 'actually obtained and the statistical analysis plan update will be finalised before breaking the', 'randomisation code.', 'Any changes from the statistical analysis planned in this clinical trial protocol will be', 'described and justified in a protocol amendment, the statistical analysis plan update and/or in', 'the CTR dependent on the type of deviation.', '12.3.11', 'Handling of missing values', 'Procedures for handling of missing values are included under the sections describing the', 'individual analyses.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 115 of 169', '13 References', '1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and', 'other health and demographic factors: a US population-based study. J Allergy Clin', 'Immunol. 2013;132(5):1132-1138.', '2. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A', 'population-based survey of eczema prevalence in the United States. Dermatitis.', '2007;18(2):82-91.', '3. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.', '4. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023)1109-1122.', '5. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis', 'is associated with a decrement in health-related quality of life. Int J Dermatol.', '2002;41(3):151-158.', '6. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for', 'treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol.', '2012;26(9):1176-1193.', '7. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al.', 'Guidelines of care for the management of atopic dermatitis: section 2. Management and', 'treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol.', '2014;71(1):116-132.', '8. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al.', 'Guidelines of care for the management of atopic dermatitis: section 3. Management and', 'treatment with phototherapy and systemic agents. J Am Acad Dermatol.', '2014;71(2):327-349', '9. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in', 'lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459-464.', '10. Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of', 'IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice', 'and humans. J Invest Dermatol. 2014;134(5):1342-1350.', '11. Aleksza M, Luk\u00e1cs A, Antal-Szalm\u00e1s P, Hunyadi J, Szegedi A. Increased frequency of', 'intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+', 'peripheral T cells of patients with atopic dermatitis. Br J Dermatol. 2002;147(6):1135-', '1141.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}